Medicine Information

Maxfer

Name: Maxfer
Brand: Maxfer
Rating: 4.5 (117 reviews)

Intravenous Injection / Infusion1 gm / 10 mLAnti-anemic Preparations, Iron PreparationsATC: B03AC08

Generic Name

Ferric Carboxymaltose

Manufacturer

Incepta Pharmaceuticals Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
maxfer 1 gm injection	৳ 1,300.00	N/A

Description

Overview of the medicine

Maxfer 1 gm Injection contains Ferric Carboxymaltose, an intravenous iron replacement product used for the treatment of iron deficiency anemia in adults.

Uses & Indications

Treatment of iron deficiency anemia (IDA) in adults who have intolerance to oral iron or who have had an unsatisfactory response to oral iron.

Treatment of IDA in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD).

Treatment of IDA in specific conditions like inflammatory bowel disease (IBD), postpartum IDA, or post-bariatric surgery.

Dosage

Adults

A total cumulative dose of up to 1000 mg (1 gm) of iron can be administered as a single dose via intravenous infusion over at least 15 minutes. Depending on the iron deficit, a second 1000 mg dose may be given 7 days after the first dose. Maximum single dose is 1000 mg.

Elderly

No specific dose adjustment is generally required. However, caution should be exercised in elderly patients with comorbidities.

Renal_impairment

No dose adjustment is usually required in patients with renal impairment, including those with non-dialysis-dependent CKD.

How to Take

Administer by intravenous infusion only. The 1000 mg dose should be infused over at least 15 minutes. Do not administer as a bolus or intramuscularly. Must be diluted as per manufacturer's instructions.

Mechanism of Action

Ferric Carboxymaltose is a non-dextran iron complex that allows controlled delivery of iron to iron-binding proteins in the body. It rapidly replenishes iron stores and effectively increases hemoglobin levels by providing bioavailable iron for erythropoiesis.

Pharmacokinetics

Onset

Rapid increase in serum iron levels; hemoglobin levels typically begin to rise within 1-2 weeks.

Excretion

Small amounts of unmetabolized iron are excreted via urine and feces. Primarily recycled within the body.

Half life

Elimination half-life of total iron is approximately 7-12 hours.

Absorption

Administered intravenously, thus 100% bioavailability. The iron complex is gradually cleared from the blood.

Metabolism

Iron is dissociated from the complex and incorporated into physiological iron stores (ferritin, hemosiderin) and hemoglobin.

Side Effects

Contraindications

Hypersensitivity to ferric carboxymaltose or to any of the excipients of the product.
Anemia not attributed to iron deficiency (e.g., other types of anemia).
Evidence of iron overload or disturbances in iron utilization.

Drug Interactions

ACE Inhibitors

No significant known interaction, but some reports suggest caution with concomitant use, especially in patients with cardiovascular issues.

Oral iron preparations

Intravenous iron may reduce the absorption of concomitantly administered oral iron preparations. Oral iron should not be started for at least 5 days after the last Maxfer injection.

Storage

Store below 30°C. Do not freeze. Protect from light. Keep out of the reach and sight of children.

Overdose

Overdose may lead to iron overload. Treatment should be based on clinical judgment. Iron chelating agents (e.g., deferoxamine) may be used if appropriate.

Pregnancy & Lactation

Pregnancy: Category B (US FDA). Use only if clearly needed and the potential benefit outweighs the potential risk to the fetus. Lactation: Limited data available; use with caution. Consult a doctor.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

1 vial of 10 mL (1 gm Ferric Carboxymaltose)

Shelf Life

24-36 months from manufacturing date, refer to specific product labeling.

Availability

Available in hospitals, clinics, and pharmacies (with prescription)

Approval Status

Approved by major regulatory bodies (e.g., FDA, EMA)

Patent Status

Proprietary, patent status varies by region

Clinical Trials

Ferric carboxymaltose has been evaluated in numerous clinical trials demonstrating its efficacy and safety in various iron deficiency anemia populations, including those with chronic kidney disease, inflammatory bowel disease, and postpartum anemia.

Lab Monitoring

Hemoglobin and hematocrit levels (to monitor response to therapy).
Serum ferritin and transferrin saturation (TSAT) (to assess iron stores).
Serum phosphate levels (due to risk of hypophosphatemia).

Doctor Notes

Monitor patients for signs and symptoms of hypersensitivity reactions, especially during and immediately after administration.
Assess iron status (Hb, ferritin, TSAT) before and after treatment to avoid iron overload.
Monitor serum phosphate levels, particularly in patients with pre-existing phosphate deficiencies or those receiving repeated doses.

Patient Guidelines

Report any allergic reactions, such as rash, itching, swelling, or difficulty breathing, to your healthcare provider immediately during or after infusion.
Do not self-administer this medicine.
Follow all post-infusion instructions given by your doctor or nurse.

Missed Dose Advice

Since this medicine is administered by a healthcare professional, a missed dose is unlikely. If a scheduled dose is missed, contact your doctor or nurse to reschedule as soon as possible.

Driving Precautions

This medicine may cause dizziness or lightheadedness. Do not drive or operate machinery until you know how Maxfer 1 gm Injection affects you.

Lifestyle Advice

Maintain a balanced diet rich in iron, as advised by your doctor.
Adhere to all follow-up appointments for monitoring your iron levels.

Alternative Medicines in Bangladesh

Similar medicines available in the market

Sucrofer (Iron Sucrose by Square Pharmaceuticals Ltd.)Ferose (Iron Sucrose by ACME Laboratories Ltd.)Monogen (Ferric Derisomaltose by Beacon Pharmaceuticals Ltd.)